^
Association details:
| Biomarker: | DNMT3A mutation + NRAS mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + idarubicin (DNA replication inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial
Published date:
11/01/2018
Excerpt:
...study has explored the role of mutation patterns determined by NGS in older AML pts...Pts received one 7+3 course followed by 2 intermediate-dose cytarabine courses…pts with a single (n=187) or ≥2 (n=38) adverse co-mutations (FLT3-ITDhighDNMT3A, ASXL1 or NRAS) had a median OS of 21.0 and 12.0 months, resp, and were considered at intermediate and high risk, resp.
DOI:
10.1182/blood-2018-99-111144
Trial ID:
